Febuxostat is superior to traditional urate-lowering agents in reducing the progression of kidney function in chronic kidney disease patients

References

• Akimoto, T., Morishita, Y., Ito, C., Iimura, O., Tsunematsu, S., Watanabe, Y., ... Nagata, D. (2014). Febuxostat for hyperuricemia in patients with advanced chronic kidney disease. Drug Target Insights, 8, 39–43. doi:10.4137/DTI.S16524
   Google Scholar
• Al-Aly, Z., Zeringue, A., Fu, J., Rauchman, M. I., McDonald, J. R., El-Achkar, T. M., ... Eisen, S. (2010). Rate of kidney function decline associates with mortality. Journal of the American Society of Nephrology, 21, 1961–1969. doi:10.1681/ASN.2009121210
   Google Scholar
• Alderman, M. H., Cohen, H., Madhavan, S., & Kivlighn, S. (1999). Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension, 34, 144–150. Retrieved from http://hyper.ahajournals.org/content/34/1/144.full.pdf+html10.1161/01.HYP.34.1.144
   Google Scholar
• Alvarez-Lario, B., & Macarron-Vicente, J. (2010). Uric acid and evolution. Rheumatology, 49, 2010–2015. doi:10.1093/rheumatology/keq204
   Google Scholar
• Becker, M. A., Schumacher, H. R., MacDonald, P. A., Lloyd, E., & Lademacher, C. (2009). Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. The Journal of Rheumatology, 36, 1273–1282. doi:10.3899/jrheum.080814
   Google Scholar
• Becker, M. A., Schumacher, Jr., H. R., Wortmann, R. L., MacDonald, P. A., Eustace, D., Palo, W. A., ... Joseph-Ridge, N. (2005). Febuxostat compared with allopurinol in patients with hyperuricemia and gout. New England Journal of Medicine, 353, 2450–2461. doi:10.1056/NEJMoa050373
   Google Scholar
• Bos, M. J., Koudstaal, P. J., Hofman, A., Witteman, J. C., & Breteler, M. M. (2006). Uric acid is a risk factor for myocardial infarction and stroke: The Rotterdam study. Stroke, 37, 1503–1507. doi:10.1161/01.STR.0000221716.55088.d4
   Google Scholar
• Brand, F. N., McGee, D. L., Kannel, W. B., Stokes, J., 3rd, & Castelli, W. P. (1985). Hyperuricemia as a risk factor of coronary heart disease: The Framingham study. American Journal of Epidemiology, 121, 11–18. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3964986
   Google Scholar
• Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., ... Levey, A. S. (2014). Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA, 311, 2518–2531. doi:10.1001/jama.2014.6634
   Google Scholar
• Doghramji, P. P., & Wortmann, R. L. (2012). Hyperuricemia and gout: New concepts in diagnosis and management. Postgraduate Medicine, 124, 98–109. doi:10.3810/pgm.2012.11.2616
   Google Scholar
• Faruque, L. I., Ehteshami-Afshar, A., Wiebe, N., Tjosvold, L., Homik, J., & Tonelli, M. (2013). A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Seminars in Arthritis and Rheumatism, 43, 367–375. doi:10.1016/j.semarthrit.2013.05.004
   Google Scholar
• Garcia-Valladares, I., Khan, T., & Espinoza, L. R. (2011). Efficacy and safety of febuxostat in patients with hyperuricemia and gout. Therapeutic Advances in Musculoskeletal Disease, 3, 245–253. doi:10.1177/1759720X11416405
   Google Scholar
• Gibson, T. (2002). Hyperuricemia, gout and the kidney. Current Opinion in Rheumatology, 24, 127–131. doi:10.1097/BOR.0b013e32834f049f
   Google Scholar
• Haririan, A., Metireddy, M., Cangro, C., Nogueira, J. M., Rasetto, F., Cooper, M., ... Weir, M. R. (2011). Association of serum uric acid with graft survival after kidney transplantation: A time-varying analysis. American Journal of Transplantation, 11, 1943–1950. doi:10.1111/j.1600-6143.2011.03613.x
   Google Scholar
• Hayden, M. R., & Tyagi, S. C. (2004). Uric acid: A new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: The urate redox shuttle. Nutrition & Metabolism, 1, 10. doi:10.1186/1743-7075-1-10
   Google Scholar
• Hosoya, T., Kimura, K., Itoh, S., Inaba, M., Uchida, S., Tomino, Y., ... Hayakawa, H. (2014). The effect of febuxostat to prevent a further reduction in renal function of patients with hyperuricemia who have never had gout and are complicated by chronic kidney disease stage 3: Study protocol for a multicenter randomized controlled study. Trials, 15, 26. doi:10.1186/1745-6215-15-26
   Google Scholar
• Jalal, D. I., Chonchol, M., Chen, W., & Targher, G. (2013). Uric acid as a target of therapy in CKD. American Journal of Kidney Diseases, 61, 134–146. doi:10.1053/j.ajkd.2012.07.021
   Google Scholar
• Johnson, R. J., Nakagawa, T., Jalal, D., Sanchez-Lozada, L. G., Kang, D. H., & Ritz, E. (2013). Uric acid and chronic kidney disease: which is chasing which? Nephrology Dialysis Transplantation, 28, 2221–2228. doi:10.1093/ndt/gft029
   Google Scholar
• Kalantar, E., Khalili, N., Hossieni, M. S., Rostami, Z., & Einollahi, B. (2011). Hyperuricemia after renal transplantation. Transplantation Proceedings, 43, 584–585. doi:10.1016/j.transproceed.2011.01.062
   Google Scholar
• Kang, D. H., Nakagawa, T., Feng, L., Watanabe, S., Han, L., Mazzali, M., ... Johnson, R.J. (2002). A role for uric acid in the progression of renal disease. Journal of the American Society of Nephrology, 13, 2888–2897. Retrieved from http://jasn.asnjournals.org/content/13/12/2888.full.pdf+html10.1097/01.ASN.0000034910.58454.FD
   Google Scholar
• Kenneth, G.S., Scott, A., Nihar, B., Maple, F., Jeff, K., Chris, S., ... Thomas, B. (2014). Lesinurad, a novel selective uric acid reabsorption inhibitor, in two phase III clinical trials: Combination study of lesinurad in allopurinol standard of care inadequate responders (CLEAR 1 and 2). ACR/ARHP Annual Meeting, Boston MA. http://acrabstracts.org/abstract/lesinurad-a-novel-selective-uric-acid-reabsorption-inhibitor-in-two-phase-iii-clinical-trials-combination-study-of-lesinurad-in-allopurinol-standard-of-care-inadequate-responders-clear-1-and-2/
   Google Scholar
• Khanna, D., Fitzgerald, J. D., Khanna, P. P., Bae, S., Singh, M. K., Neogi, T., ... Terkeltaub, R. (2012). 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care & Research, 64, 1431–1446. doi:10.1002/acr.21772
   Google Scholar
• Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. L., Castro, A. F., 3rd, Feldman, H. I., ... Coresh, J. (2009). A new equation to estimate glomerular filtration rate. Annals of Internal Medicine, 150, 604–612. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2763564/pdf/nihms132246.pdf10.7326/0003-4819-150-9-200905050-00006
   Google Scholar
• Levin, A., Djurdjev, O., Beaulieu, M., & Er, L. (2008). Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. American Journal of Kidney Diseases, 52, 661–671. doi:10.1053/j.ajkd.2008.06.023
   Google Scholar
• Little, R. J. A., & Rubin, D. B. (2002). Missing data in experiments. In N. J. Hoboken (Ed.), Statistical analysis with missing data (2nd ed., pp. 24–40). Hoboken, NJ: Wiley. doi:10.1002/9781119013563
   Google Scholar
• Liu, B., Wang, T., Zhao, H. N., Yue, W. W., Yu, H. P., Liu, C. X., ... Nie, H.W. (2011). The prevalence of hyperuricemia in China: A meta-analysis. BMC Public Health, 11, 832. doi:10.1186/1471-2458-11-832
   Google Scholar
• Liu, W. C., Hung, C. C., Chen, S. C., Yeh, S. M., Lin, M. Y., Chiu, Y. W., ... Chen, H. C. (2012). Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clinical Journal of the American Society of Nephrology, 7, 541–548. doi:10.2215/CJN.09420911
   Google Scholar
• Matsushita, K., Mahmoodi, B. K., Woodward, M., Emberson, J. R., Jafar, T. H., Jee, S. H., ... Levey, A. S. (2012). Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA, 307, 1941–1951. doi:10.1001/jama.2012.3954
   Google Scholar
• Matsushita, K., Selvin, E., Bash, L. D., Franceschini, N., Astor, B. C., & Coresh, J. (2009). Change in estimated GFR associates with coronary heart disease and mortality. Journal of the American Society of Nephrology, 20, 2617–2624. doi:10.1681/ASN.2009010025
   Google Scholar
• Mazzali, M., Kanellis, J., Han, L., Feng, L., Xia, Y. Y., Chen, Q., ... Johnson, R. J. (2002). Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. American Journal of Physiology - Renal Physiology, 282, F991–F997. doi:10.1152/ajprenal.00283.2001
   Google Scholar
• Nakagawa, T., Mazzali, M., Kang, D. H., Sánchez-Lozada, L. G., Herrera-Acosta, J., & Johnson, R. J. (2006). Uric acid – a uremic toxin? Blood Purif, 24, 67–70. doi:10.1159/000089440
   Google Scholar
• Park, S. H., Shin, W. Y., Lee, E. Y., Gil, H. W., Lee, S. W., Lee, S. J., ... Hong, S. Y. (2011). The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention. Circulation Journal, 75, 692–697. Retrieved from https://www.jstage.jst.go.jp/article/circj/75/3/75_CJ-10-0631/_pdf10.1253/circj.CJ-10-0631
   Google Scholar
• Schumacher, H. R., Jr, Becker, M. A., Lloyd, E., MacDonald, P. A., & Lademacher, C. (2009). Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford), 48, 188–194. doi:10.1093/rheumatology/ken457
   Google Scholar
• Schumacher, H. R., Jr, Becker, M. A., Wortmann, R. L., MacDonald, P. A., Hunt, B., Streit, J., ... Joseph-Ridge, N. (2008). Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis & Rheumatism, 59, 1540–1548. doi:10.1002/art.24209
   Google Scholar
• Smith, E. U., Díaz-Torné, C., Perez-Ruiz, F., & March, L. M. (2010). Epidemiology of gout: An update. Best Practice & Research Clinical Rheumatology, 24, 811–827. doi:10.1016/j.berh.2010.10.004
   Google Scholar
• Somkrua, R., Eickman, E. E., Saokaew, S., Lohitnavy, M., & Chaiyakunapruk, N. (2011). Association of HLA-B*5801 allele and allopurinol-induced stevens johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis. BMC Medical Genetics, 12, 43–119. doi:10.1186/1471-2350-12-118
   Google Scholar
• Tassaneeyakul, W., Jantararoungtong, T., Chen, P., Lin, P. Y., Tiamkao, S., Khunarkornsiri, U., ... Tassaneeyakul, W. (2009). Strong association between HLA-B*5801 and allopurinol-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenetics and Genomics, 19, 704–709. doi:10.1097/FPC.0b013e328330a3b8
   Google Scholar
• Vázquez-Mellado, J., Alvarez Hernández, E., & Burgos-Vargas, R. (2004). Primary prevention in rheumatology: The importance of hyperuricemia. Best Practice & Research Clinical Rheumatology, 18, 111–124. doi:10.1016/j.berh.2004.01.001
   Google Scholar
• Weng, S. C., Shu, K. H., Tarng, D. C., Cheng, C. H., Chen, C. H., Yu, T. M., ... Wu, M. J. (2014). Uric acid is highly associated with kidney allograft survival in a time-varying analysis. Transplantation Proceedings, 46, 505–510. doi:10.1016/j.transproceed.2013.09.038
   Google Scholar
• Weng, S. C., Tarng, D. C., Chen, C. M., Cheng, C. H., Wu, M. J., Chen, C. H., ... Shu, K. H. (2014). Estimated glomerular filtration rate decline is a better risk factor for outcomes of systemic disease-related nephropathy than for outcomes of primary renal diseases. PLoS ONE, 9, e92881. doi:10.1371/journal.pone.0092881
   Google Scholar